All In Biotech

Drug Trial Radar · NCT07925775

Immunogenicity and Safety of SYS6057 in the Participants Aged 18 Years and Above

A Randomized, Blinded, Placebo-Controlled, Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of SYS6057 (Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)) Administered to Participants Aged 18 Years and Older

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Oct 31, 2026

Primary completion

Mar 31, 2027

Study completion Feb 28, 2028

Sponsor

Sponsor type
Industry
First posted
Nov 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Human respiratory syncytial virus (RSV) is an enveloped, non-segmented, single-stranded negative-sense RNA virus. It is one of the most common pathogens causing acute lower respiratory infection (ALRI) in infants, young children, and older adults worldwide. Vaccination with an RSV vaccine can prevent lower respiratory tract disease caused by RSV infection. We are conducting a randomized, blinded, placebo-controlled, Phase I clinical trial to evaluate the safety and immunogenicity of SYS6057 (Recombinant Respiratory Syncytial Virus Vaccine (CHO cell)) in individuals aged 18 years and older.

Conditions

  • Lower Respiratory Tract Disease Caused by RSV Infection

Interventions

  • Investigational vaccine low doseBiological

    Investigational vaccine low dose

  • Investigational vaccine high doseBiological

    Investigational vaccine high dose

  • PlaceboBiological

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. solicited adverse eventsTime frame: within 14 days post vaccination
  2. unsolicited adverse eventsTime frame: within 30 days post vaccination

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.